dehydroretronecine

major pyrrole metabolite of monocrotaline; RN given refers to cpd without isomeric designation

Also Known As:

6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine; dehydro-retronecine; dehydroheliotridine; dehydroretro-necine; dehydroretronecine, (R)-isomer; dehydroretronecine, (S)-isomer

Networked: 11 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Pyrrolizidine Alkaloids: 290
    - Monocrotaline: 1629
      - dehydroretronecine: 11
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Pyrrolizidine Alkaloids: 290
      - Monocrotaline: 1629
        dehydroretronecine: 11

Experts

1.	Fu, Peter P: 5 articles (02/2019 - 05/2004)
2.	Xia, Qingsu: 5 articles (02/2019 - 05/2004)
3.	Chou, Ming W: 3 articles (05/2008 - 05/2004)
4.	Lin, Ge: 2 articles (02/2019 - 05/2004)
5.	Tolleson, William H: 2 articles (02/2019 - 01/2014)
6.	He, Xiaobo: 1 article (02/2019)
7.	Wu, Qiangen: 1 article (02/2019)
8.	Li, Meng: 1 article (01/2014)
9.	Wang, Chia-Chi: 1 article (01/2014)
10.	Wang, Shuguang: 1 article (01/2014)

Related Diseases

1.	Neoplasms (Cancer) 07/01/1978 - "Dehydroretronecine-induced skin tumors in mice." 02/01/1983 - "Neoplasia and chronic disease associated with the prolonged administration of dehydroheliotridine to rats." 04/01/1976 - "Of 60 rats that received dehydroretronecine, 39 developed rhabdomyosarcomas at the injection site, and 5 of these neoplasms metastasized. " 07/01/1978 - "Female Swiss mice susceptible to skin tumors received 6 sc injections and/or topical applications of dehydroretronecine, a metabolite of the pyrrolizidine alkaloid monocrotaline, and were observed for 15 months for tumor development. " 02/01/1983 - "When dehydroheliotridine (DHH), a pyrrolizidine alkaloid metabolite with bifunctional alkylating and antimitotic activities, was administered to a hooded strain of rats by ip injection, the incidence of tumors, excluding interstitial cell tumors, was significantly greater than that in saline-injected controls. "
2.	Leydig Cell Tumor 02/01/1983 - "When dehydroheliotridine (DHH), a pyrrolizidine alkaloid metabolite with bifunctional alkylating and antimitotic activities, was administered to a hooded strain of rats by ip injection, the incidence of tumors, excluding interstitial cell tumors, was significantly greater than that in saline-injected controls. "
3.	Phototoxic Dermatitis (Phototoxicity) 01/01/2014 - "In this study, the phototoxicity of monocrotaline, riddelliine, dehydromonocrotaline, dehydroriddelliine, and dehydroretronecine (DHR) in human HaCaT keratinocytes under ultraviolet A (UVA) irradiation was determined. "
4.	Rhabdomyosarcoma 04/01/1975 - "Dehydroretronecine-induced rhabdomyosarcomas in rats." 04/01/1976 - "Of 60 rats that received dehydroretronecine, 39 developed rhabdomyosarcomas at the injection site, and 5 of these neoplasms metastasized. " 04/01/1975 - "Rhabdomyosarcomas developed at the site of dehydroretronecine injection in 51.6% of the rats and in 3.3% of the monocrotaline-treated rats. "
5.	Pulmonary Heart Disease (Cor Pulmonale) 01/01/1977 - "Pulmonary heart disease induced by disenecioyl dehydroretronecine: a semisynthesis pyrrolizidine alkaloid pyrrole."

Related Drugs and Biologics

1.	Pyrrolizidine Alkaloids
2.	Antimitotic Agents
3.	riddelliine
4.	DNA Adducts
5.	retronecine
6.	Monocrotaline
7.	monocrotaline pyrrole
8.	otonecine
9.	clivorine
10.	lasiocarpine

Related Therapies and Procedures

1.	Injections